BACKGROUND: HIV-1 circulating recombinant forms (CRF) containing subtype B are uncommon in sub-Saharan Africa. Prevalent infections observed during enrollment of a prospective study of men who have sex with men (MSM) from Lagos, Nigeria, revealed the presence of a family of subtype B and CRF02_AG recombinants. This report describes the HIV-1 genetic diversity within a high-risk, high-prevalence, and previously undersampled cohort of Nigerian MSM. METHODS: Between 2013 and 2016, 672 MSM were enrolled at the Lagos site of the TRUST/RV368 study. Prevalent HIV-1 infections were initially characterized by pol sequencing and phylogenetic subtyping analysis. Samples demonstrating the presence of subtype B were further characterized by near full-length sequencing, phylogenetic, and Bayesian analyses. RESULTS: Within this cohort, HIV-1 prevalence was 59%. The major subtype was CRF02_AG (57%), followed by CRF02/B recombinants (15%), subtype G (13%), and smaller amounts of A1, B, and other recombinants. Nine clusters of closely related pol sequences indicate ongoing transmission events within this cohort. Among the CRF02_AG/B, a new CRF was identified and termed CRF95_02B. Shared risk factors and Bayesian phylogenetic inference of the new CRF95_02B and the similarly structured CRF56_cpx indicate a Nigerian or West African origin of CRF56_cpx before its observation in France. CONCLUSION: With high HIV-1 prevalence, new strains, and multiple transmission networks, this cohort of Nigerian MSM represents a previously hidden reservoir of HIV-1 strains, including the newly identified CRF95_02B and closely related CRF56_cpx. These strains will need to be considered during vaccine selection and development to optimize the design of a globally effective HIV-1 vaccine.
BACKGROUND:HIV-1 circulating recombinant forms (CRF) containing subtype B are uncommon in sub-Saharan Africa. Prevalent infections observed during enrollment of a prospective study of men who have sex with men (MSM) from Lagos, Nigeria, revealed the presence of a family of subtype B and CRF02_AG recombinants. This report describes the HIV-1 genetic diversity within a high-risk, high-prevalence, and previously undersampled cohort of Nigerian MSM. METHODS: Between 2013 and 2016, 672 MSM were enrolled at the Lagos site of the TRUST/RV368 study. Prevalent HIV-1 infections were initially characterized by pol sequencing and phylogenetic subtyping analysis. Samples demonstrating the presence of subtype B were further characterized by near full-length sequencing, phylogenetic, and Bayesian analyses. RESULTS: Within this cohort, HIV-1 prevalence was 59%. The major subtype was CRF02_AG (57%), followed by CRF02/B recombinants (15%), subtype G (13%), and smaller amounts of A1, B, and other recombinants. Nine clusters of closely related pol sequences indicate ongoing transmission events within this cohort. Among the CRF02_AG/B, a new CRF was identified and termed CRF95_02B. Shared risk factors and Bayesian phylogenetic inference of the new CRF95_02B and the similarly structured CRF56_cpx indicate a Nigerian or West African origin of CRF56_cpx before its observation in France. CONCLUSION: With high HIV-1 prevalence, new strains, and multiple transmission networks, this cohort of Nigerian MSM represents a previously hidden reservoir of HIV-1 strains, including the newly identified CRF95_02B and closely related CRF56_cpx. These strains will need to be considered during vaccine selection and development to optimize the design of a globally effective HIV-1 vaccine.
Authors: J C Chen; J Krucinski; L J Miercke; J S Finer-Moore; A H Tang; A D Leavitt; R M Stroud Journal: Proc Natl Acad Sci U S A Date: 2000-07-18 Impact factor: 11.205
Authors: Gustavo H Kijak; Sodsai Tovanabutra; Chris Beyrer; Eric E Sanders-Buell; Miguel A Arroyo; Merlin L Robb; Nelson L Michael; Francine E McCutchan; Jerome H Kim Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205
Authors: Wenjie Deng; Brandon S Maust; David C Nickle; Gerald H Learn; Yi Liu; Laura Heath; Sergei L Kosakovsky Pond; James I Mullins Journal: Biotechniques Date: 2010-05 Impact factor: 1.993
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Trevor A Crowell; Gustavo H Kijak; Eric Sanders-Buell; Anne Marie O'Sullivan; Afoke Kokogho; Zahra F Parker; John Lawlor; Christina S Polyak; Sylvia Adebajo; Rebecca G Nowak; Stefan D Baral; Merlin L Robb; Manhattan E Charurat; Julie A Ake; Nicaise Ndembi; Sodsai Tovanabutra Journal: Antivir Ther Date: 2019
Authors: Will Fischer; Elena E Giorgi; Srirupa Chakraborty; Kien Nguyen; Tanmoy Bhattacharya; James Theiler; Pablo A Goloboff; Hyejin Yoon; Werner Abfalterer; Brian T Foley; Houriiyah Tegally; James Emmanuel San; Tulio de Oliveira; Sandrasegaram Gnanakaran; Bette Korber Journal: Cell Host Microbe Date: 2021-06-03 Impact factor: 31.316
Authors: Paul E Oluniyi; Fehintola V Ajogbasile; Shuntai Zhou; Iyanuoluwa Fred-Akintunwa; Christina S Polyak; Julie A Ake; Sodsai Tovanabutra; Michael Iroezindu; Morgane Rolland; Christian T Happi Journal: AIDS Date: 2022-01-01 Impact factor: 4.632
Authors: Nicaise Ndembi; Fati Murtala-Ibrahim; Monday Tola; Jibreel Jumare; Ahmad Aliyu; Peter Alabi; Charles Mensah; Alash'le Abimiku; Miguel E Quiñones-Mateu; Trevor A Crowell; Soo-Yon Rhee; Robert W Shafer; Ravindra Gupta; William Blattner; Manhattan E Charurat; Patrick Dakum Journal: AIDS Res Ther Date: 2020-11-03 Impact factor: 2.250